Skip to main content

Predictmedix AI Showcased in Toronto Star Newspaper; Accelerates Oxygen Saturation Parameter to Accommodate Widespread Respiratory Health Issues

TORONTO, ON / ACCESSWIRE / September 12, 2023 / Predictmedix AI Inc. (CSE:PMED)(OTCQB:PMEDF)(FRA:3QP) (the "Company" or "Predictmedix") is proud to announce its recent feature in the prestigious Toronto Star newspaper, accompanied by a compelling interview with the company's COO, Dr. Rahul Kushwah. This exciting development marks a significant milestone in Predictmedix's journey, enhancing the company's visibility and attracting both business opportunities and investor attention.

The spotlight on Predictmedix AI in the Toronto Star underscores the company's commitment to cutting-edge technology and innovation in the healthcare sector. With the rapid advancements in AI and healthcare, Predictmedix continues to set industry standards by introducing ground-breaking solutions that has the potential to revolutionize patient care at scale.

Predictmedix AI has successfully accelerated development and deployment of AI algorithms capable of contactlessly identifying Oxygen saturation levels (SPO2). The measurement of oxygen saturation plays a crucial role in the management of patients with various health conditions, including chronic obstructive pulmonary disease (COPD), asthma, pneumonia, lung cancer, anemia, heart failure, heart attack, and other cardiopulmonary disorders.

What sets the Safe Entry system apart is its exceptional accuracy, with a 97 percent success rate demonstrated in live testing. This innovation was initially developed at the request of government officials in India, where respiratory health issues are a growing concern.

"The recognition in the Toronto Star and the opportunity to discuss our vision and innovations is a testament to the hard work and dedication of the entire Predictmedix team," commented Dr. Rahul Kushwah, COO of Predictmedix AI. "We believe that technology has the power to transform healthcare, and Safe Entry, with its ground-breaking AI algorithms for contactless SPO2 measurement, is a prime example of how we're making a tangible impact on patient care. Our technology can revolutionize the entire respiratory medicine division in India and provide valuable insights for healthcare professionals and policymakers."

Predictmedix AI's dedication to advancing healthcare through AI-driven solutions has garnered widespread attention, and the company remains committed to pushing the boundaries of innovation in healthcare technology.

About Predictmedix AI Inc.

Predictmedix AI Inc. (CSE:PMED) (OTCQB:PMEDF) (FRA:3QP) is an emerging provider of rapid health screening and remote patient care solutions globally. The Company's Safe Entry Stations - powered by a proprietary artificial intelligence (AI) - use multispectral cameras to analyze physiological data patterns and predict a variety of health issues including infectious diseases such as COVID-19, impairment by drugs or alcohol, fatigue, or various mental illnesses. Predictmedi AI's proprietary remote patient care platform empowers medical professionals with a suite of AI-powered tools to improve patient health outcomes. To learn more, please visit our website at or follow us on Twitter, Instagram or LinkedIn.

Public Relations Contact

For further media information or to set up an interview, please contact:

Nelson Hudes Hudes
Communications International (905) 660 9155

Dr. Rahul Kushwah (647) 889 6916

Caution Regarding Forward-Looking Information:

This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results of the Company. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances. The Company's securities have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"), or applicable state securities laws, and may not be offered or sold to, or for the account or benefit of, persons in the United States or "U.S. Persons", as such term is defined in Regulations under the U.S. Securities Act, absent registration or an applicable exemption from such registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or any jurisdiction in which such offer, solicitation or sale would be unlawful. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any Page 4 of 4 future results, performance or achievements expressed or implied by the forward-looking information contained herein, such as, but not limited to dependence on obtaining regulatory approvals; the ability to obtain intellectual property rights related to its technology; limited operating history; general business, economic, competitive, political, regulatory and social uncertainties, and in particular, uncertainties related to COVID-19; risks related to factors beyond the control of the Company, including risks related to COVID-19; risks related to the Company's shares, including price volatility due to events that may or may not be within such party's control; reliance on management; and the emergency of additional competitors in the industry.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except required by law.

Disclaimer: "The Company is not making any express or implied claims that its product has the ability to diagnose, eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus) at this time.


SOURCE: Predictmedix AI Inc.

View source version on

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.